Clinical impact of panel-based next-generation sequencing in a real-world cohort of neuroblastoma patients.
Journal of Clinical Oncology · 2026-05-27
Phase II trial of olaparib and ceralasertib in patients with recurrent osteosarcoma: Lung-only resectable cohort efficacy and correlative biomarker results.
Journal of Clinical Oncology · 2026-05-27
Safety and feasibility of cabozantinib (CABO) in combination with cisplatin, doxorubicin, and high-dose methotrexate (MAP) in patients with newly diagnosed high-risk osteosarcoma (OS).
Journal of Clinical Oncology · 2026-05-27
An international framework for clinical translation of molecular classifiers in osteosarcoma
npj Precision Oncology · 2026-05-05
Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study
JCO Precision Oncology · 2026-05-01
Abstract 643: The Sean Karl Cohort: An international single-cell RNAseq study of paired patient Ewing sarcoma specimens.
Cancer Research · 2026-04-03
Genome-wide association study meta-analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk
medRxiv · 2026-02-09
Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies
Communications Medicine · 2026-01-23
Appendix1 from A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group
2026-01-06
Supplementary Material1 from A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group
2026-01-06
Data from A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group
2026-01-06
Considerations for Clinical Trial Design in Relapsed and Refractory Osteosarcoma: An FDA Symposium
Clinical Cancer Research · 2026-01-02 · 2 citations
Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children’s Oncology Group
International Journal of Radiation Oncology*Biology*Physics · 2025-11-22 · 1 citations
<i>MYC</i> amplification and MYC protein expression are poor prognostic markers in pediatric and young adult osteosarcoma
Cancer · 2025-11-06 · 3 citations
Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Journal of Clinical Oncology · 2025-11-03 · 4 citations
A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group
Clinical Cancer Research · 2025-10-29
PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study
JCO oncology advances. · 2025-10-01
Germline Cancer Predisposition Results From the National Cancer Institute—Children's Oncology Group Pediatric MATCH Trial
JCO Precision Oncology · 2025-10-01 · 3 citations
Abstract A016: ews-nf: A custom workflow for tumor cell annotation and analysis of single-cell RNA-sequencing of paired patient Ewing sarcoma specimens from the Sean Karl cohort
Cancer Research · 2025-09-25
Abstract A003: The clinical impact of targeted next-generation sequencing for advanced pediatric and AYA sarcoma patients in the iCat2/GAIN Consortium Study
Cancer Research · 2025-09-25